agilon Health falls on new short report from Citron Research
Geber86/E+ via Getty Images


agilon Health (NYSE:AGL) dropped 5.7% after Citron Research released a new short report with downside to $5/share, representing 81% drop from Tuesday's close.
Citron alleges that Agilon has a "nosebleed" valuation relative to its peers and it has a problematic business model.

Agilon Health (AGL), a primary-care service provider, jumped 3.8% on Thursday after competitor One Medical (ONEM) agreed to be sold to Amazon (AMZN) for $18/share, or about $3.9 billion including debt. Agilon shares fell 8.3% on Friday following the Thursday surge.
Agilon (AGL) declined to comment to Seeking Alpha on the report.
AGL short interest is 11%.

AGL is scheduled to release Q2 results next Thursday.